5α-还原酶抑制剂联合多西他赛在前列腺癌治疗中的疗效分析
|
摘要
目的研究5α-还原酶抑制剂联合多西他赛在前列腺癌治疗中的疗效,为临床用药提供新方案。方法对前列腺癌患者68例,采用手术去势后内分泌联合化疗治疗。根据去势后所用药物的不同分为观察组和对照组。观察组采用5α-还原酶抑制剂(非那雄胺)联合多西他赛,对照组采用比卡鲁胺联合多西他赛。结果与对照组相比,治疗组治疗期间总有效率明显提高(P<0.05),PSA均在正常范围内,排尿梗阻和骨痛症状改善更为明显(P<0.05),各时间点KPS评分均显著增高(P<0.05),无进展生存时间和中位生存期也都明显提高(P<0.05),差异均具有显著性。结论5α-还原酶抑制剂联合多西他赛治疗前列腺癌疗效显著,值得临床推广。
Objective To evaluate the therapeutic efficacy of 5α-reductase inhibitor combined with docetaxel in the treatment of prostate cancer,and provide new solution for clinical medication. Methods 68 patients with prostate cancer who met the adoption standard were selected. After castration operation,the endocrine combined chemotherapy was used for treatment. The patients were divided into the observation group and the control group according to the different drugs used after operation. The observation group was given 5α-reductase inhibitor combined with docetaxel,while the control group was given bicalutamide combined with docetaxel. Results Compared with the control group,the total effective rate during treatment in the observation group significantly increased( P < 0. 05),PSA level were within the normal range,urination obstruction and bone pain were improved more significantly( P < 0. 05),KPS scores in different times were significantly increased( P < 0. 05),and progression-free survival time and median survival time also increased obviously( P < 0. 05),so all differences were significant. Conclusion 5α-reductase inhibitor combined with docetaxel has a significant therapeutic efficacy on prostate cancer treatment,which is worthy of popularizing in clinical application.
Objective To evaluate the therapeutic efficacy of 5α-reductase inhibitor combined with docetaxel in the treatment of prostate cancer,and provide new solution for clinical medication. Methods 68 patients with prostate cancer who met the adoption standard were selected. After castration operation,the endocrine combined chemotherapy was used for treatment. The patients were divided into the observation group and the control group according to the different drugs used after operation. The observation group was given 5α-reductase inhibitor combined with docetaxel,while the control group was given bicalutamide combined with docetaxel. Results Compared with the control group,the total effective rate during treatment in the observation group significantly increased( P < 0. 05),PSA level were within the normal range,urination obstruction and bone pain were improved more significantly( P < 0. 05),KPS scores in different times were significantly increased( P < 0. 05),and progression-free survival time and median survival time also increased obviously( P < 0. 05),so all differences were significant. Conclusion 5α-reductase inhibitor combined with docetaxel has a significant therapeutic efficacy on prostate cancer treatment,which is worthy of popularizing in clinical application.
引文
[1]Kimura T.East meets West:ethnic differences in prostate cancer epidemiology between East Asians and Caucasians[J].Chin J Cancer,2012,31(9):421-429.
[2]Dai J,Lu Y,Roca H,et al.Immune mediators in the tumor microenvironment of prostate cancer[J].Chin J Cancer,2017,36(1):29.
[3]刘成.134例前列腺癌患者的临床分析[D].南昌大学,2014.
[4]朱岑,杜文清,程斯倩.雄激素抵抗型前列腺癌的治疗现状及进展[J].吉林医药学院学报,2012,33(3):171-176.
[5]王晓琳.晚期前列腺癌治疗药[J].药学研究,2011,30(7)432-434.
[6]Valkenburg KC,Steensma MR,Williams BO,et al.Skeletal metastasis:treatments,mouse models,and the Wnt signaling[J].Chin J Cancer,2013,32(7):380-396.
[7]Qin JJ,Wang W,Voruganti S,et al.Identification of a new class of natural product MDM2 inhibitor:In vitro and in vivo anti-breast cancer activities and target validation[J].Oncotarget,2015,6(5):2623-2640.
[8]业辉,聂品,江文,等.前列腺癌骨转移预测因素[J].南方医学杂志,2016,36(2):205-209.
[9]万克松,胡卫列,夏照明,等.手术去势间断联合抗雄激素药物治疗晚期前列腺癌临床疗效分析[J].实用医学杂志,2012,28(3):421-423.
[10]郭晨煜,孙永旭,祝伟伟,等.多西他赛不良反应及处理对策研究进展[J].中国药房,2013,24(48):4598-4602.
[11]徐州.5α-还原酶抑制剂联合α受体阻断剂治疗前列腺癌增生的临床疗效[J].临床合理用药,2015,8(7):1306-1308.
[12]曹洪富,诸明娜.多西他赛联合比卡鲁胺应用于前列腺癌治疗的不良反应[J].贵州医药,2016,40(11):1178-1179.
[13]钱苏波,齐隽.5-α还原酶抑制剂在前列腺癌预防及治疗中的应用[J].现代泌尿外科杂志,2014,19(9):268-272.
[14]黄宇星,刘二伟.联合用药的药物相互作用及研究方法[J].药理评价研究,2014,37(3):276-279.
[15]谢雁鸣,王连心.临床联合用药知己研究的探讨[J].中国中药杂志,2014,39(18):3424-3426.
[16]戴波,翟元元,孔蕴毅,等.PSA倍增时间对去势抵抗性前列腺癌患者多西他赛化疗后总生存期的影响[J].临床泌尿外科杂志,2013,28(2):113-117.
[17]曹万里.以PSA为基础的前列腺癌筛查研究的探讨[J].中华男科学杂志,2013,19(6):559-562.
[18]肖二龙,李涛.5-α还原酶抑制剂对前列腺癌的预防作用[J].临床泌尿外科杂志,2013,28(12):953-956.
[2]Dai J,Lu Y,Roca H,et al.Immune mediators in the tumor microenvironment of prostate cancer[J].Chin J Cancer,2017,36(1):29.
[3]刘成.134例前列腺癌患者的临床分析[D].南昌大学,2014.
[4]朱岑,杜文清,程斯倩.雄激素抵抗型前列腺癌的治疗现状及进展[J].吉林医药学院学报,2012,33(3):171-176.
[5]王晓琳.晚期前列腺癌治疗药[J].药学研究,2011,30(7)432-434.
[6]Valkenburg KC,Steensma MR,Williams BO,et al.Skeletal metastasis:treatments,mouse models,and the Wnt signaling[J].Chin J Cancer,2013,32(7):380-396.
[7]Qin JJ,Wang W,Voruganti S,et al.Identification of a new class of natural product MDM2 inhibitor:In vitro and in vivo anti-breast cancer activities and target validation[J].Oncotarget,2015,6(5):2623-2640.
[8]业辉,聂品,江文,等.前列腺癌骨转移预测因素[J].南方医学杂志,2016,36(2):205-209.
[9]万克松,胡卫列,夏照明,等.手术去势间断联合抗雄激素药物治疗晚期前列腺癌临床疗效分析[J].实用医学杂志,2012,28(3):421-423.
[10]郭晨煜,孙永旭,祝伟伟,等.多西他赛不良反应及处理对策研究进展[J].中国药房,2013,24(48):4598-4602.
[11]徐州.5α-还原酶抑制剂联合α受体阻断剂治疗前列腺癌增生的临床疗效[J].临床合理用药,2015,8(7):1306-1308.
[12]曹洪富,诸明娜.多西他赛联合比卡鲁胺应用于前列腺癌治疗的不良反应[J].贵州医药,2016,40(11):1178-1179.
[13]钱苏波,齐隽.5-α还原酶抑制剂在前列腺癌预防及治疗中的应用[J].现代泌尿外科杂志,2014,19(9):268-272.
[14]黄宇星,刘二伟.联合用药的药物相互作用及研究方法[J].药理评价研究,2014,37(3):276-279.
[15]谢雁鸣,王连心.临床联合用药知己研究的探讨[J].中国中药杂志,2014,39(18):3424-3426.
[16]戴波,翟元元,孔蕴毅,等.PSA倍增时间对去势抵抗性前列腺癌患者多西他赛化疗后总生存期的影响[J].临床泌尿外科杂志,2013,28(2):113-117.
[17]曹万里.以PSA为基础的前列腺癌筛查研究的探讨[J].中华男科学杂志,2013,19(6):559-562.
[18]肖二龙,李涛.5-α还原酶抑制剂对前列腺癌的预防作用[J].临床泌尿外科杂志,2013,28(12):953-956.